See more : ISP Holdings Limited (2340.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Imunon, Inc. (CLSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imunon, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Brookfield Reinsurance Ltd. (BNRE-A) Income Statement Analysis – Financial Results
- Kusuri No Aoki Holdings Co., Ltd. (3549.T) Income Statement Analysis – Financial Results
- 5th Planet Games A/S (IDGAF) Income Statement Analysis – Financial Results
- Ensysce Biosciences, Inc. (ENSCW) Income Statement Analysis – Financial Results
- Xinxiang Tianli Energy Co., Ltd. (301152.SZ) Income Statement Analysis – Financial Results
Imunon, Inc. (CLSN)
About Imunon, Inc.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 11.25M | 12.32M | 2.51M | 0.00 | 0.00 | 0.00 | 3.42K | 100.00K | 174.18K | 121.26K | 74.01K |
| Cost of Revenue | 720.01K | 731.63K | 702.92K | 11.34M | 13.07M | 11.07M | 13.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.67M | 8.11M | 2.10M | 0.00 | 0.00 | 0.00 | -39.23K | 0.00 | 136.50K | 46.73K | 64.41K |
| Gross Profit | -720.01K | -231.63K | -202.92K | -10.84M | -12.57M | -10.57M | -12.58M | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 4.58M | 4.21M | 405.34K | 0.00 | 0.00 | 0.00 | 42.65K | 100.00K | 37.68K | 74.52K | 9.60K |
| Gross Profit Ratio | 0.00% | -46.33% | -40.58% | -2,168.96% | -2,513.06% | -2,113.10% | -2,515.74% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 40.72% | 34.15% | 16.17% | 0.00% | 0.00% | 0.00% | 1,247.13% | 100.00% | 21.63% | 61.46% | 12.97% |
| Research & Development | 11.29M | 11.73M | 10.62M | 11.34M | 13.07M | 11.87M | 13.08M | 14.62M | 14.66M | 14.97M | 9.36M | 15.77M | 19.86M | 14.71M | 13.68M | 12.01M | 8.23M | 9.35M | 10.08M | 11.53M | 8.18M | 5.00M | 4.08M | 2.24M | 1.00M | 1.53M | 185.97K | 94.01K |
| General & Administrative | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 0.00 | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 0.00 | 0.00 | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 390.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 5.15M | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 3.47M | 5.13M | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Other Expenses | 0.00 | 5.40M | 1.62M | -1.30M | 3.19M | 3.63M | 651.97K | 733.00K | -259.45K | 265.89K | -2.53K | -1.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 14.08M | 13.49M | 15.00M | 13.30M | 9.84M | 7.29M | 4.94M | 2.40M | 4.05M | 2.47M | 1.43M |
| Cost & Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 20.75M | 21.60M | 17.11M | 13.30M | 9.84M | 7.29M | 4.90M | 2.40M | 4.19M | 2.52M | 1.50M |
| Interest Income | 960.55K | 502.58K | 18.15K | 66.55K | 442.99K | 331.78K | 26.04K | 31.26K | 186.32K | 1.02M | 748.95K | 0.00 | 174.06K | 32.29K | 46.16K | 221.71K | 0.00 | 636.56K | 299.25K | 0.00 | 30.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.57M | 557.00K | 1.29M | 1.39M | 712.03K | 91.76K | 693.00K | 1.36M | 1.33M | 915.24K | 307.00K | 501.86K | 31.52K | 94.92K | 141.61K | 49.42M | 1.10M | 179.59K | 0.00 | -13.27M | -9.75M | -6.92M | 0.00 | 0.00 | 199.35K | 0.00 | 85.51K |
| Depreciation & Amortization | 720.01K | 731.63K | 702.92K | 741.52K | 721.67K | 356.86K | 553.01K | 1.03M | 424.97K | 369.33K | 339.23K | 281.49K | 176.86K | 172.98K | 109.65K | 69.47K | -39.11K | -341.29K | -321.39K | -275.68K | 100.53K | 82.44K | 68.85K | 39.48K | -100.00K | 24.29K | 24.17K | 18.55K |
| EBITDA | -19.88M | -31.71M | -20.88M | -21.30M | -16.55M | -21.23M | -19.76M | -20.30M | -20.67M | -23.79M | -6.99M | -25.92M | -22.54M | -18.61M | -15.80M | -11.58M | -13.13M | -9.84M | -9.50M | -14.78M | -13.20M | -9.79M | -7.26M | -4.86M | -2.40M | -3.99M | -2.37M | -1.40M |
| EBITDA Ratio | 0.00% | -3,905.20% | -3,877.00% | -3,795.72% | -3,242.17% | -3,349.10% | -3,447.48% | -3,983.40% | -4,098.99% | -4,335.91% | -2,865.17% | 0.00% | -1,133.39% | 0.00% | 0.00% | -463.01% | 0.00% | -94.55% | -77.14% | -589.83% | 0.00% | 0.00% | 0.00% | -142,016.75% | -2,300.00% | -2,296.79% | -1,960.88% | -1,936.39% |
| Operating Income | -21.03M | -24.92M | -21.01M | -18.49M | -20.57M | -21.07M | -18.47M | -20.65M | -20.85M | -24.72M | -15.41M | -22.14M | -23.02M | -19.64M | -17.01M | -11.55M | -13.59M | -8.49M | -9.28M | -14.60M | -13.30M | -9.84M | -7.29M | -4.90M | -2.30M | -4.01M | -2.39M | -1.42M |
| Operating Income Ratio | 0.00% | -4,984.40% | -4,201.40% | -3,697.28% | -4,113.09% | -4,213.01% | -3,693.69% | -4,130.00% | -4,169.36% | -4,943.04% | -3,082.30% | 0.00% | -1,150.94% | 0.00% | 0.00% | -461.98% | 0.00% | -75.43% | -75.32% | -582.51% | 0.00% | 0.00% | 0.00% | -143,171.08% | -2,300.00% | -2,303.92% | -1,974.89% | -1,922.52% |
| Total Other Income/Expenses | 235.07K | -12.54M | -1.15M | -4.84M | 1.90M | -1.24M | -1.93M | -1.40M | -1.61M | -779.08K | 7.16M | -4.43M | -203.91K | 818.99K | 1.01M | -236.80K | -483.23K | 902.40K | -96.89K | 613.90K | 30.38K | 86.61K | 363.65K | 349.24K | -100.00K | -187.48K | -657.19K | -510.69K |
| Income Before Tax | -20.80M | -37.47M | -22.15M | -23.33M | -18.67M | -22.30M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -16.00M | -11.79M | -14.07M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Income Before Tax Ratio | 0.00% | -7,493.00% | -4,430.60% | -4,665.88% | -3,733.60% | -4,460.49% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| Income Tax Expense | -1.28M | -1.57M | -1.38M | -1.85M | -1.82M | -10.42M | 1.93M | 1.40M | 1.61M | 779.08K | 1.00 | 4.43M | 203.91K | -818.99K | -806.00K | 236.80K | -49.42M | -1.91M | 8.69M | -613.90K | 13.27M | 9.75M | 6.92M | 4.55M | 2.40M | 187.48K | 657.19K | 510.69K |
| Net Income | -19.51M | -35.90M | -20.77M | -21.48M | -16.85M | -11.88M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -15.19M | -11.79M | 35.35M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Net Income Ratio | 0.00% | -7,179.60% | -4,153.80% | -4,296.71% | -3,370.31% | -2,376.67% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| EPS | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.43 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 3.11K | -668.10 | -765.29 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -105.01 | -1.52K | -1.09K |
| EPS Diluted | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.42 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 2.90K | -668.10 | -760.54 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -193.97 | -1.52K | -1.09K |
| Weighted Avg Shares Out | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 11.36K | 11.35K | 11.35K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 40.00K | 2.00K | 1.78K |
| Weighted Avg Shares Out (Dil) | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 12.18K | 11.35K | 11.42K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 21.66K | 2.00K | 1.78K |
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a...
Why Celsion's Stock Is Ripping Higher Today
Celsion Corporation (NASDAQ: CLSN) shares are trading at their highest level since early July after the company terminated a stock sale agreement. Celsion revealed in SEC filing it has notified Lincoln Park Capital Fund regarding termination of the stock purchase...
CLSN Stock Alert: 5 Things to Know About Celsion as Shares Soar
Celsion (CLSN) stock is soaring higher Thursday on heavy trading and InvestorPlace has all the details investors need to know. The post CLSN Stock Alert: 5 Things to Know About Celsion as Shares Soar appeared first on InvestorPlace.
Celsion stock rockets on heavy volume again; share sale agreement with LPC was terminated
Shares of Celsion Corp. shot up 85.1% toward a six-month high in very active premarket trading Thursday, putting the on track to more than double in two days, after the cancer drug development company disclosed that it terminated the share...
CLSN Stock Price Increases Over 30% Pre-Market: Why It Happened
The stock price of Celsion Corporation (NASDAQ: CLSN) has increased by over 30% pre-market today. This is why it happened.
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation.
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, Dec. 28, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) for violations of §§10(b) and 20(a)...
CLSN Final Deadline Tomorrow: Rosen, Top Ranked National Investor Attorneys, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action - CLSN
New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class...
CLSN Final Deadline Tomorrow: Rosen, Top Ranked National Investor Attorneys, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action - CLSN
New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class...
DEC. 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN
NEW YORK, Dec. 26, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”).
Source: https://incomestatements.info
Category: Stock Reports